Aldeyra Therapeutics (ALDX) Expected to Announce Earnings on Wednesday

Aldeyra Therapeutics (NASDAQ:ALDX) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.13) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. On average, analysts expect Aldeyra Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Trading Up 6.2%

ALDX opened at $1.72 on Wednesday. The business’s 50 day moving average is $2.75 and its 200-day moving average is $4.23. The stock has a market cap of $103.75 million, a PE ratio of -3.02 and a beta of 1.16. Aldeyra Therapeutics has a twelve month low of $1.07 and a twelve month high of $6.18.

Analysts Set New Price Targets

ALDX has been the subject of a number of analyst reports. HC Wainwright reiterated a “neutral” rating and set a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. Finally, Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aldeyra Therapeutics presently has an average rating of “Hold” and an average price target of $5.50.

Insider Transactions at Aldeyra Therapeutics

In related news, Director Richard Douglas purchased 70,000 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were bought at an average price of $1.40 per share, with a total value of $98,000.00. Following the completion of the acquisition, the director owned 195,000 shares of the company’s stock, valued at approximately $273,000. This represents a 56.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in Aldeyra Therapeutics by 275.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after buying an additional 1,081,257 shares during the period. Kennedy Capital Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 61.9% in the third quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock worth $5,806,000 after buying an additional 425,245 shares during the period. Bank of America Corp DE increased its position in shares of Aldeyra Therapeutics by 590.5% in the third quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock worth $2,036,000 after acquiring an additional 333,587 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Aldeyra Therapeutics by 49.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 313,395 shares during the period. Finally, Two Sigma Investments LP grew its position in Aldeyra Therapeutics by 389.9% during the 3rd quarter. Two Sigma Investments LP now owns 273,054 shares of the biotechnology company’s stock worth $1,425,000 after purchasing an additional 217,315 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.